Effect of obesity on the population pharmacokinetics of meropenem in critically ill patients

Alobaid, Abdulaziz S., Wallis, Steven C., Jarrett, Paul, Starr, Therese, Stuart, Janine, Lassig-Smith, Melissa, Ordonez Mejia, Jenny Lisette, Roberts, Michael S., Lipman, Jeffrey and Roberts, Jason A. (2016) Effect of obesity on the population pharmacokinetics of meropenem in critically ill patients. Antimicrobial Agents and Chemotherapy, 60 8: 4577-4584. doi:10.1128/AAC.00531-16

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ406459_OA.pdf Full text (open access) application/pdf 956.06KB 0

Author Alobaid, Abdulaziz S.
Wallis, Steven C.
Jarrett, Paul
Starr, Therese
Stuart, Janine
Lassig-Smith, Melissa
Ordonez Mejia, Jenny Lisette
Roberts, Michael S.
Lipman, Jeffrey
Roberts, Jason A.
Title Effect of obesity on the population pharmacokinetics of meropenem in critically ill patients
Journal name Antimicrobial Agents and Chemotherapy   Check publisher's open access policy
ISSN 1098-6596
Publication date 2016-08-01
Sub-type Article (original research)
DOI 10.1128/AAC.00531-16
Open Access Status File (Publisher version)
Volume 60
Issue 8
Start page 4577
End page 4584
Total pages 8
Place of publication Washington, DC, United States
Publisher American Society for Microbiology
Collection year 2017
Language eng
Formatted abstract
Severe pathophysiological changes in critical illness can lead to dramatically altered antimicrobial pharmacokinetics (PK). The additional effect of obesity on PK potentially increases the challenge for effective dosing. The aim of this prospective study was to describe the population PK of meropenem for a cohort of critically ill patients, including obese and morbidly obese patients. Critically ill patients prescribed meropenem were recruited into the following three body mass index (BMI) groups: nonobese (18.5 to 29.9 kg/m2), obese (30.0 to 39.9 kg/m2), and morbidly obese (≥40 kg/m2). Serial plasma samples were taken, and meropenem concentrations were determined using a validated chromatographic method. Population PK analysis and Monte Carlo dosing simulations were undertaken with Pmetrics. Nineteen critically ill patients with different BMI categories were enrolled. The patients' mean ± standard deviation (SD) age, weight, and BMI were 49 ± 15.9 years, 95 ± 22.0 kg, and 33 ± 7.0 kg/m2, respectively. A two-compartment model described the data adequately. The mean ± SD parameter estimates for the final covariate model were as follows: clearance (CL), 15.5 ± 6.0 liters/h; volume of distribution in the central compartment (V1), 11.7 ± 5.8 liters; intercompartmental clearance from the central compartment to the peripheral compartment, 25.6 ± 35.1 liters h-1; and intercompartmental clearance from the peripheral compartment to the central compartment, 8.32 ± 12.24 liters h-1. Higher creatinine clearance (CLCR) was associated with a lower probability of target attainment, with BMI having little effect. Although obesity was found to be associated with an increased V1, dose adjustment based on CLCR appears to be more important than patient BMI.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 25 Sep 2016, 10:30:01 EST by System User on behalf of Learning and Research Services (UQ Library)